Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  DeNardo, Sally J ^a,c   DeNardo, Gerald L ^a   DeNardo, David G ^a   Xiong, Cheng Yi ^a   Shi, Xu Bao ^a   Winthrop, Michelle D ^a   Kroger, Linda A ^a   Carter, Paul ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANCE N,N',N'',N''' TETRAACETIC ACID; ACETIC ACID DERIVATIVE; ANTIBODY; CYCLAM DERIVATIVE; DNA; HLA DR ANTIGEN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; BACTERIOPHAGE; CANCER THERAPY; CONFERENCE PAPER; DNA FINGERPRINTING; DNA SEQUENCE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE LIBRARY; HUMAN; HYBRIDOMA; IMMUNOGLOBULIN GENE; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANIMALS; BACTERIOPHAGES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MOLECULAR WEIGHT; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 0032724110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., and Stern, H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet., 28: 126-142, 1995.
2. DeNardo, G. L., DeNardo, S. J., Lewis, J. P., Mills, S. L., O'Grady, L. F., Levy, N. B., and Maddock, S. W. Treatment of B-cell malignancies in patients using fractionated dose (FD) or maximum tolerated dose (MTD) of I-131 Lym-1 without and with immunophoresis. J. Nucl. Med., 32: 921-922, 1991.
3. DeNardo, S. J., Mirick, G. R., Kroger, L. A., O'Grady, L. F., Erickson, K. L., Yuan, A., Lamborn, K. R., Hellstrom, I., Hellstrom, K. E., and DeNardo, G. L. The biologic window for chimeric L6 radioimmunotherapy. Cancer (Phila.), 73 (Suppl.): 1023-1032, 1994.
4. Chester, K. A., and Hawkins, R. E. Advances in antibody technology for targeted cancer therapy. Tumor Marker Update, 6: 187-195, 1994.
5. Vaughan, T. J., William, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., and Johnson, K. S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol., 14: 309-314, 1996.
6. Chester, K. A., Begent, R. H., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A., Winter, G., and Cochet, O. Phage libraries for generation of clinically useful antibodies. Lancet, 343: 455-456, 1994.
7. Winthrop, M. D., DeNardo, S. J., and DeNardo, G. L. Development of a hyperimmune anti-MUC-1 scFv antibody phage display library for targeting breast cancer. Clin. Cancer Res., 5 (Suppl.): 3088s-3094s, 1999.
8. DeNardo, S. J., DeNardo, G. L., Brush, J., and Carter, P. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. Hybridoma, 18: 13-21, 1999.
9. Feng, X., Pak, R. H., Kroger, L. A., Moran, J. K., DeNardo, D. G., Meares, C. F., DeNardo, G. L., and DeNardo, S. J. New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma, 17: 125-132, 1998.
10. Zhu, Z., Zapata, G., Shalaby, R., Snedecor, B., Chen, H., and Carter, P. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology, 14: 192-196, 1996.
11. Carter, P., Ridgway, J., and Zhu, Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother., 4: 463-470, 1995.
12. Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res., 53: 4026-4034, 1993.
13. Adams, G. P., Schier, R., McCall, A. M., Crawford, S. M., Wolff, E. J., Weiner, M., and Marks, J. D. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer, 77: 1405-1412, 1998.
14. Holliger, P., Prospero, T., and Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 90: 6444-6448, 1993.
15. Desplancq, D., King, D. J., Lawson, A. D. G., and Mountain, A. Multimerization behavior of single chain Fv variants for the tumor-binding antibody B72.3. Protein Eng., 7: 1027-1033, 1994.
16. Whitlow, M., Filpula, D., Rollence, M. L., Feng, S. L., and Wood, J. F. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng., 7: 1017-1026, 1994.
17. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
18. Moi, M. K., Meares, C. F., and DeNardo, S. J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,-N′,N″, N‴-tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc., 110: 6266-6267, 1988.
19. Moi, M. K., Meares, C. F., McCall, M. J., Cole, W. C., and DeNardo, S. J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 148: 249-253, 1985.
20. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjugate Chem., 1: 222-226, 1990.
21. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
22. Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A. J., Dodd, S. W., Wood, J. F., Whitlow, M., Snoy, P., and Schlom, J. Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res., 51: 6363-6371, 1991.
23. Glockshuber, R., Malia, M., Pfitzinger, I., and Pluckthun, A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry, 29: 1362-1367, 1990.
24. Batra, J. K., FitzGerald, D., Gately, M., Chaudhary, V. K., and Pastan, I. Anti-Tac (Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. J. Biol. Chem., 265: 15198-15202, 1990.
25. Freund, C., Ross, A., Guth, B., Pluckthun, A., and Holak, T. Characterization of the linker peptide of the single-chain Fv fragment of an antibody by NMR spectroscopy. FEBS Lett., 320: 97-100, 1993.
26. Huston, J. S., Margolies, M. N., and Haber, E. Antibody binding sites. Adv. Protein Chem., 49: 329-450, 1996.
27. Winter, G., and Milstein, C. Man-made antibodies. Nature (Lond.), 349: 293-299, 1991.
28. Potter, H. Electroporation in biology: methods, applications, and instrumentation. Anal. Biochem., 174: 361-373, 1988.
29. Vieira, J., and Messing, J. Production of single-stranded plasmid DNA. Methods Enzymol., 153: 3-11, 1987.
30. Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P., and Winter, G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res., 19: 4133-4137, 1991.
31. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. Making antibody fragments using phage display libraries. Nature (Lond.), 352: 624-628, 1991.
32. Huston, J. S., McCartney, J., Tai, M. S., Mottola-Hartshorn, C., Jin, D., Warren, F., Keck, P., and Oppermann, H. Medical applications of single-chain antibodies. Int. Rev. Immunol., 10: 195-217, 1993.
33. Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., and Allison, T. J. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J., 13: 3245-3260, 1994.
34. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222: 581-597, 1991.
35. Harrison, J. L., Williams, S. C., Winter, G., and Nissim, A. Screening of phage antibody libraries. Methods Enzymol., 267: 83-109, 1996.
36. Hawkins, R. E., Russell, S. J., and Winter, G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol., 226: 889-896, 1992.
37. Hoogenboom, H. R. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol., 15: 62-70, 1997.
38. Bruggemann, M., and Taussig, M. J. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol., 8: 455-458, 1997.
39. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol., 12: 433-455, 1994.
40. McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (Lond.), 348: 552-554, 1990.
41. Johnson, K. S., and Chiswell, D. J. Human antibody engineering. Curr. Opin. Struct. Biol., 3: 564-521, 1993.
42. Johnson, K. S., and Hawkins, R. J. Affinity maturation of antibodies using phage display. In: H. R. McCafferty, H. R. Hoogenboom, and D. J. Chiswell (eds.), Antibody Engineering: A Practical Approach, pp. 41-58. Oxford, United Kingdom: IRL Press, 1996.
43. Begent, R. H., Verhaar, M. J., Chester, K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2: 979-984, 1996.
44. Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., and Weiner, L. M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res., 58: 485-490, 1998.
45. Marks, C., and Marks, J. D. Phage libraries: a new route to clinically useful antibodies. N. Engl. J. Med., 335: 730-733, 1996.
46. Schier, R., McCall, A., Adams, G. P., Marshall, K. W., Merritt, H., Yim, M., Crawford, R. S., Weiner, L. M., Marks, C., and Marks, J. D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol., 263: 551-567, 1996.
47. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., Kukis, D. L., Meares, C. F., Yuan, A., Welborn, J. L., and DeNardo, G. L. Yttrium-90/Indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
48. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res., 18: 2779-2788, 1998.
49. Shi, X. B., Gumerlock, P. H., Wellman, A. A., Meares, C. F., DeNardo, G. L., Meyers, F. J., and DeNardo, S. J. Rapid PCR construction of a gene containing Lym-1 antibody variable regions. PCR Methods Applications, 3: 46-53, 1993.
50. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol., 16: 3246-3256, 1998.
51. 131I-Lym-1 antibody. Cancer Biother. Radiopharm., 13: 239-254, 1998.
52. Shi, X. B., Gumerlock, P. H., Kroger, L. A., DeNardo, G. L., and DeNardo, S. J. Efficient recombination of Lym-1 scFv gene using multiple doubly-restricted DNA fragments. Cancer Biother. Radiopharm., 14: 139-143, 1999.
53. Kohler, G., and Milstein, C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256: 495-497, 1975.
54. Jain, R. K. Haemodynamic and transport barriers to the treatment of solid tumours. Int. J. Radiat. Biol., 60: 85-100, 1991.
55. Pack, P., and Pluckthun, A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry, 31: 1579-1584, 1992.
56. Pack, P., Schroechk, V., Knupfer, U., Wenderoth, R., Riesenberg, D., and Pluckthun, A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology, 11: 1271-1277, 1993.
57. Hu, S. Z., Raubitschek, A., Sherman, A., Williams, L. E., Wong, J. Y., Shively, J. E., and Wu, A. M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain-Fv-Ch3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 56: 3055-3061, 1996.